The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

A 2025 review shows India’s preterm birth rate at 13%. With over 23% of global preterm births, nearly 150,000 Indian infants ...

Going for a regular eye check-up is about more than assessing your ability to see. Your eyes can be a window to early ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study ...

A recent study published in the Journal of Cataract & Refractive Surgery found that Yttrium Aluminum Garnet (YAG) laser ...

Diabetic Retinopathy Patient Summit organized by Dr Agarwals Eye Hospitals, across India Group offers Free diabetic eye ...

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Housing instability, food insecurity and other factors related to social deprivation come with significantly greater risks ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

Diabetic eye damage can begin early, even before diagnosis, silently threatening vision. Early screenings and lifestyle ...